Related Experiment Video
Updated: Apr 12, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Identification of the interaction network of hub genes for melanoma treated with vemurafenib based on microarray data
Liangliang Quan1, Yang Wang, Jiulong Liang
1Department of Plastic Surgery, General Hospital of Shenyang Military Area Command, PLA, Liaoning - China.
Aims And Background:
The objective of this study was to identify possible biomarkers and to explore the mechanisms of suppression of vemurafenib on melanoma progression.
Methods:
GSE42872 affymetrix microarray data were downloaded from the Gene Expression Omnibus database for further analysis. Differentially expressed genes (DEGs) between vehicle-treated samples and vemurafenib-treated samples were identified. Gene ontology and pathway enrichment analysis of DEGs were performed, followed by protein-protein interaction (PPI) network construction. Furthermore, the functional modules of the PPI network were screened using BioNet analysis tool. Finally, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis was performed for DEGs in the module.
Results:
In total, 794 upregulated transcripts corresponding to 214 genes and 977 downregulated transcripts corresponding to 325 genes were screened. The downregulated DEGs were significantly enriched in pathways such as cell cycle, DNA replication, and p53 signaling pathway. Upregulated DEGs were significantly enriched in phosphatidylinositol signaling system and inositol phosphate metabolism. Significantly enriched functions of downregulated DEGs were mitotic cell cycle, nuclear division, DNA metabolic process, cell cycle, and mitosis. Upregulated DEGs were mainly enriched in single multicellular organism process and multicellular organismal process. Moreover, cell division cycle 6, checkpoint kinase 1 (CHEK1), E2F transcription factor 1 (E2F1), epidermal growth factor receptor (EGFR), and phosphoinositide-3-kinase, regulatory subunit 1-α (PIK3R1) of the module were remarkably enriched in pathways such as cell cycle, apoptosis, focal adhesion, and DNA replication.
Conclusions:
Cell division cycle 6, CHEK1, E2F1, EGFR, and PIK3R1 of the module and their relative pathways, cell cycle, and focal adhesion might play important roles of suppression of vemurafenib on melanoma progression.
Insights
Vemurafenib suppresses melanoma progression by impacting cell cycle and focal adhesion pathways. Key genes identified include Cell division cycle 6, CHEK1, E2F1, EGFR, and PIK3R1, offering potential therapeutic targets.
Area of Science:
- Genomics and Bioinformatics
- Melanoma Research
- Molecular Biology
Background:
- Melanoma is a significant skin cancer with complex progression mechanisms.
- Vemurafenib is a targeted therapy for melanoma, but its precise suppression mechanisms require further elucidation.
Purpose of the Study:
- To identify potential biomarkers for vemurafenib's effect on melanoma.
- To explore the molecular mechanisms underlying vemurafenib's suppression of melanoma progression.
Main Methods:
- Analysis of Gene Expression Omnibus (GEO) dataset GSE42872 using affymetrix microarray data.
- Identification of differentially expressed genes (DEGs) between vemurafenib-treated and vehicle-treated melanoma samples.
- Gene Ontology, pathway enrichment, and protein-protein interaction (PPI) network analyses, including BioNet screening and KEGG pathway analysis.
Main Results:
- Identified 794 upregulated and 977 downregulated transcripts.
- Downregulated DEGs were enriched in cell cycle, DNA replication, and p53 signaling pathways.
- Upregulated DEGs were enriched in phosphatidylinositol signaling and inositol phosphate metabolism pathways.
- Key genes within a significant module (Cell division cycle 6, CHEK1, E2F1, EGFR, PIK3R1) were associated with cell cycle, apoptosis, focal adhesion, and DNA replication pathways.
Conclusions:
- Cell division cycle 6, CHEK1, E2F1, EGFR, and PIK3R1, along with cell cycle and focal adhesion pathways, are implicated in vemurafenib's suppression of melanoma progression.
- These findings suggest potential therapeutic targets and mechanistic insights for vemurafenib therapy in melanoma.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
DNA Microarrays
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression

